OPKO Health (NASDAQ:OPK) Shares Rise After Q2 Earnings Exceed Forecasts; Nicoya Agreement Lifts After-Hours Gains

OPK ended regular trading on July 27 at $1.24, rising 1.6%. After-hours, the stock advanced to approximately $1.34–$1.35, up roughly 8%–9%. The move followed a narrower loss, revenue above expectations, and an improved outlook. The after-hours high was around $1.50, close to the 52-week high of $1.61. The upcoming regular session on Tuesday will determine if the advance persists. The Wall Street Journal

OPKO posted a per-share loss of $0.01, compared with the consensus loss estimate of $0.08. Revenue reached $163.6 million, topping the forecast of $131.2 million by $32.4 million. Of that revenue, $29.4 million was from Nicoya preferred shares received as consideration. Adjusting for that, revenue was roughly $134.1 million. The core revenue beat was thus closer to $2.9 million, not $32.4 million. The prior-year results factored in a $91.7 million note-exchange expense. MarketBeat

Management increased its revenue outlook to $560–$585 million, up from a previous estimate of $530–$560 million. Projected costs and expenses were revised lower to a range of $710–$740 million from the prior $725–$750 million. The uplift in revenue was mainly due to gains in IP and other revenue, with this range raised to $100–$105 million from $70–$80 million. Services guidance declined to $296–$306 million, while product forecasts rose to $164–$174 million. Q3 revenue is projected at $131–$142 million, a significant drop from the Q2 figure. The raised outlook is driven primarily by transaction-related activity rather than widespread operating growth. Opko Health

Not when adjusted. Diagnostics revenue dropped to $74.5 million from $101.1 million compared to the previous year, which had included $24.9 million from oncology assets that have since been divested. Revenue from retained diagnostics operations was still lower by about $1.7 million, or nearly 2%. The segment posted $4.8 million in operating income for Q2, which included an $18.1 million gain related to a Labcorp earnout. Excluding this gain, the segment recorded a loss of roughly $13.3 million. Opko Health

As of June 30, cash, securities, and restricted cash stood at $314.4 million, a decrease of $27.5 million from March 31. OPKO allocated $13.2 million toward the repurchase of 9.7 million shares over the quarter. There is $94.7 million still authorized for repurchases, equivalent to about 10% of Monday’s market cap. Long-term convertible notes and royalty financing reached approximately $336.6 million. The headline liquidity total factors in cash under restriction. The balance sheet remains functional, but net cash reserves appear limited. Opko Health

NGENLA profit-share revenue totaled $12.8 million in the first half of 2026. Executives continue to project $34–$37 million for the full year, implying the need for $21.2–$24.2 million in the latter half. This would be a 66%–89% rise over first-half levels. Management attributes this to contract terms that lead to much higher revenue in the back half of the year. RAYALDEE Q2 sales climbed 12.5% year-on-year to $8.1 million. Performance remains strongly tied to Pfizer and other international partners. Opko Health

Q2 4Kscore revenue declined to $6.3 million compared with $6.9 million. Management noted that volumes marginally missed internal forecasts for 2026. Broader expansion through primary care remains dependent on positive decisions from Medicare and Novitas. The company anticipates double-digit growth after changes to reimbursement policies. Management projects the more significant effect will occur in 2027 or beyond, but the timeline remains unclear. Opko Health

Enrollment for MDX2301 is projected to complete in Q3, with initial data anticipated by late 2026 or early 2027. MDX2001 has reached 39 patients enrolled, and first data is also expected in that period. The in-vivo CAR-T program may advance to Phase 1 as soon as late 2026 or early 2027. OPK-88006 is currently recruiting for a Phase 1/2a MASH study involving 44 participants. A once-weekly acromegaly candidate is targeted to begin trials before year-end. The majority of catalysts remain at an early stage. Timelines and outcomes are subject to change. Opko Health

Key risk is that investors may overlook one-off accounting gains. Core diagnostics performance deteriorated, and 4Kscore reimbursement progress remains significantly delayed. Q3 revenue guidance at $136.5 million midpoint is 16.5% lower than Q2’s reported figure. Cash position fell, and R&D expenses for the quarter increased to $33.2 million. Major pipeline readouts are still months away and could be postponed further. Sustained rally requires more robust recurring growth. Opko Health